CX157
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code | none |
Legal status | |
Legal status |
|
Identifiers | |
| |
PubChem (CID) | 18687754 |
ChemSpider | 13701383 |
Chemical and physical data | |
Formula | C14H8F4O4S |
Molar mass | 348.27 g/mol |
3D model (Jmol) | Interactive image |
| |
| |
(verify) |
CX157 (proposed trade name TriRima, formerly Tyrima) is a selective and reversible inhibitor of MAO-A (RIMA).[1] As of 2007 it was in phase II clinical trials for the treatment of depression.[2] In 2013, it was discontinued for both depression and anxiety.
References
- ↑ Fielding R, Mielach F, Free J, Pande A (2007). Pharmacokinetics and oral bioavailability of CX157, a reversible selective MAO-A inhibitor, in primates (PDF). 2007 AAPS Annual Meeting & Exposition. Retrieved 2009-06-14.
- ↑ Clinical trial number NCT00739908 at ClinicalTrials.gov
This article is issued from Wikipedia - version of the 9/2/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.